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1.1 Placental development 
 
While the derivation of the word placenta from Latin meaning cake, as well as the 
German term “Mutterkuchen“ and the cake-shaped gross anatomy could indicate a fairly easy 
structure the placenta is in fact a functionally highly complex organ. A proper vascular 
development inside the placenta is therefore a key feature to maintain a pregnancy (1). 
Increasing nutritional needs of the blastocyst entering the uterus around the 5th day post 
fertilization requires its implantation into the uterine wall. Apposition, adhesion and invasion 
are the chronological steps of this process (2). The outer layer of the blastocyst will 
differentiate into trophoblast, which will later on be further subdivided in villous trophoblast 
(cytotrophoblast and syncytiotrophoblast) and EVTB (interstitial and endovascular). While 
the villous trophoblast, as their name already indicates will form the chorionic villi, the EVTB 
will further penetrate the decidua and spiral arteries (1). At around 11 days’ post fertilization 
primary villi, which are fingerlike protrusions consisting of cytotrophoblast covered by 
syncytiotrophoblast into the maternal decidua, are formed. Their invasion with 
extraembryonic mesoderm by day 16 is differentiating them into secondary villi (2). These 
mesenchymal cells will differentiate into hemangioblastic cell cords and perivascular cells, 
precursors of capillary endothelial cell (1). Furthermore, Hofbauer cells, which are 
macrophages expanding during the first and second trimester in the villi, are also of 
mesenchymal origin (1). Hofbauer cells are linked to trophoblast differentiation, migration 
and angiogenesis by producing various growth factors and cytokines (1). The result after three 
weeks are tertiary villi which are floating in a maternal blood space and can be subdivided 
into stem villi (connected to the chorionic plate, supportive function for the villi structure), 
terminal villi (floating within the intervillous space, functional unit of the placenta) or 
anchoring villi (2). The placenta is not perfused with maternal blood until about 12 weeks due 
to the blockage of the spiral arteries by endovascular trophoblast (3). Another theory states 
that the nonperfusion is simply caused by the time endovascular trophoblast need migrating 
and replacing the smooth muscle along the decidual spiral arteries (1). The remodeling of the 
spiral artery is an indispensable event for placental development. This process is creating a 
high-flow, low-resistance environment for adequate nutrition. The first changes of this 
process are independent of trophoblast and may be due to a paracrine-autocrine set of 
interactions between smooth muscle and endothelial cells (3).  
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The reduction of number of smooth muscle cells is then further accelerated by the NO 
production and deposition of fibrinoid material inside the vessel wall by invading trophoblast 
(3). Impaired trophoblast invasion as well as insufficient conversion of spiral arteries leads to 
decreased placental blood flow and is associated with several pregnancy diseases (2, 3). At 
term the placenta presents a disc liked shaped organ with a diameter of about 22 cm, a 
thickness of 2,5 cm in the middle and an average weight of 470 g. The placenta at term 
consists of a chorionic plate at the fetal and a basal plate at the maternal site (Figure 1). The 
chorionic plate is covered by amnion consisting of a single layered epithelium and avascular 
connective tissue (4). Accumulations of fibrin in the intervillous space gives the fetal surface 
a white mottled appearance (5). The umbilical cord containing the vessels merges with the 
chorionic mesenchyme inserting the chorionic plate usually at a slightly eccentrically point 
(Figure 2). Forming from the villous trees, the chorionic arteries will give rise to two 
umbilical arteries while the single umbilical vein intersects underneath the chorionic arteries. 
Whereas the fetal site manifests on gross anatomy shiny and transparent the maternal site 
rather displays a fine granular appearance due to the separation of the placenta from the 
uterine wall during delivery. The basal site is subdivided into 10-40 lobes called cotyledons 
by placental septa (4). A mixture of trophoblast, decidual cells, extracellular debris, fibrinoid 
and blood clots forms the basal plate. On a microscopic view the variation of the width in the 
intervillous space increased from first to third trimester reaching an average width of 16-32 
mm. Significant variations from this mean indicate increased branching or deficiency of 
terminal villi and is associated with disease. In normal at term placentas the terminal villi 
make up nearly 50% of the total villous surface, despite their small diameters (5). Their 
separation of fetal vessel and syncytiotrophoblast only by a thin basement membrane makes 
them the superior villi for diffusive exchange compared to the other forms (4). Mesenchymal 
villi, which were the first villous type present at the development of the placenta, are still 
found but in low numbers at the time of the delivery. The bulbous, peripheral immature villi 
that are abundant between weeks 8 and 22 will decrease parallel to the number of 
mesenchymal villi found at term (5). 
 Immature intermediate villi are differentiated by their loose stroma, Hofbauer cells 
(placental macrophages), more prominent vessels and a discontinuous cytotrophoblast layer 
(4). The villi with the largest diameter and an anchoring function are the stem villi, developed 
from differentiating immature villi by fibrinization of the stroma (5). The fifth subtype of 
placental villi are long, slender precursors of terminal villi called mature intermediate villi. 
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Figure 1. Gross appearance of maternal side of the placenta  
(Figure taken from mentor's archive) 
 
 
Figure 2. Gross appearance of placental cut surface with umbilical cord  
(Figure taken from mentor's archive)
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1.2 HELLP syndrome 
 
1.2.1 Definition and epidemiology of HELLP 
 
Weinstein described HELLP syndrome as a new spectrum of the preeclamptic/ 
eclamptic disorder in order to raise awareness and make earlier recognition possible (6). The 
acronym H (hemolysis), EL (elevated liver enzymes), and a low platelet count (LP) is still 
used today and refers to the abnormal laboratory variants in the syndrome. In the Tennesse 
Classification System diagnostic criteria for HELLP are hemolysis, increased LDH (>600 
U/L) and platelets (< 100x10^9/L). The HELLP syndrome can be further divided into a 
complete form (requiring all three characters of the triad) or incomplete (consisting of only 1 
or 2 elements). 
There is also one more classification called the Mississippi triple class system dividing 
HELLP syndrome into three classes based on their platelet count (7). 
The majority of cases of HELLP syndrome seem to develop rather ante partum (70%) 
with a peak frequency between the 27th and 37th gestational weeks (8, 9). In total 0,5-0,9% of 
all pregnancies and 10-20% of cases of severe preeclampsia are affected by HELLP syndrome 
(7). According to a review article from Curtin and Weinstein the maternal mortality ranges 
from 0-4% (10).  
 
1.2.2 Risk Factors and Pathophysiology 
 
HELLP syndrome seems to be more common in Caucasian women, while African 
American women demonstrate higher levels of hypertension in severe preeclampsia (11, 12). 
A previous pregnancy with preeclampsia or HELLP syndrome means a relative high risk of 
recurrence of HELLP in the second pregnancy (7, 13, 14). Chronic hypertension, multiple 
pregnancies, nulliparous and age over 35 are additional risk factors, while a BMI above 30 
and diabetes seem to only influence the risk of the first pregnancy (13, 15). Furthermore, 
HELLP syndrome seems to have a higher incidence in patients with antiphospholipid 
syndrome (16, 17). Interestingly regarding our further work HELLP syndrome seems also to 
be associated with some genetic variations, like FAS gene (18).  
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While a high BMI and metabolic syndrome 6 months postpartum as well as a greater 
risk at the first pregnancy are associated with preeclampsia, those factors seem not to 
influence HELLP pathogenesis (19).  
Moreover, some differences in the clinical manifestations of HELLP syndrome and 
preeclampsia raised the question in several papers whether HELLP syndrome is a variant of 
preeclampsia or an entity of its own. A study from the Dutch genome-wide scan proposed for 
example that HELLP syndrome and preeclampsia might have different backgrounds due to 
their linkages on chromosomes (preeclampsia on chromosomes 10q and 22q, HELLP on 12q) 
(20).  
Further differences were found in the vascular reactivity of patients with PE or 
HELLP and might be due to distinct alterations of the vasculature (21). If we take a closer 
look into the maternal blood values, we will recognize higher levels of fetal mRNA coding for 
Flt1 (VEGFR-1) and Eng as well as soluble HLA-DR (sHLA-DR) compared to preeclampsia 
(19). Moreover, we would detect a more enhanced inflammatory response with higher 
concentrations of CRP, Interleukin 6 and TNF-alpha in the maternal blood sample (19). There 
also seems to be a higher consumption of coagulation inhibitors and activation of fibrinolysis 
in patients with HELLP syndrome displaying its greater endothelial damage (22). This result 
matches with the higher incidence of DIC in this group (23). Proliferation markers in 
cytotrophoblastic cells and placental expression of FAS Ligand (FasL) are higher in HELLP 
(24, 25). In addition, decidual dendritic cells stained differently in HELLP and displayed 
interaction with natural killer cells and VEGFR-1 and -2 (26). Vinnars found higher rates of 
infarction, intervillous thrombosis, abruption and placental weight in the preeclampsia group 
and concluded this might be due to different underlying pathogenic mechanisms (27). 
However, in a later study in 2010 she did not find the differences in intervillous thrombosis, 
placental abruption or placental weight again (28).  
In contrast to the first thesis of Vinnars, Smulian and Weiner describe most placental 
histopathological lesions in preeclampsia and HELLP as similar and suspect that they share 
similar placental injuries (11, 29). They therefore concluded to see severe preeclampsia and 
HELLP syndrome not as separated conditions and instead see them as variations of one 
disease. In accordance to the previous discussion some researchers suspect that HELLP 
syndrome as a variant of preeclampsia shares most of its pathophysiological features (10, 11, 
19, 29). 
 
 
  
 
 
7 
The main pathophysiological mechanism of preeclampsia seems to be ischemia and 
endothelial dysfunction (30). In one hypothesis immune maladaptation between decidual 
leukocytes and invading cytotrophoblast is suspected to be the cause for the shallow invasion 
of spiral arteries (31).  
The insufficient trophoblast invasion and unconverted narrow spiral arteries are 
suspected as cause for the hypoxia (32). The placenta releases as response angiogenic agents, 
cytokines, products of lipid peroxidation, autoantibodies and placental cell debris. Later on 
anti-angiogenic factors causing an imbalance between anti-angiogenic factors and angiogenic 
factors are raising (33). Clinical symptoms like hypertension and proteinuria are supposed to 
be due to increased circulating antiangiogenic proteins like sFlt-1 (= VEGFR-1), endoglin 
(34). These factors cause an enhanced inflammatory immune response by triggering the 
vascular endothelium (19). Furthermore, lipid peroxidation and leukocyte activation may be 
attributed key roles in the mechanism of endothelial dysfunction (35). It is suspected that the 
resulting angiopathy involves circulating platelets, causing hemolysis in affected microvessels 
and by narrowing of the vessel lumen causing reduced hepatic blood flow. Hepatic injury 
seems also to be caused by placenta-derived FasL (CD95L) which is toxic to human 
hepatocytes (36). 
Recent findings showed evidence of a complement system dysregulation in 
preeclampsia and HELLP syndrome (37, 38). The maladaptation between decidual leukocytes 
and invading cytotrophoblast offers one explanation to the theory of an immunologically 
mediated cause of the disease. Another theory suggests a dysfunctional lipid metabolism as 
contributing factor to HELLP syndrome, recognizing the negative correlation of maternal 
platelet counts and serum TG levels (39). Additionally, the higher frequency of preeclampsia-
related conditions in long chain 3-hydroxyacylcoenzyme A deficient fetus further supports the 
idea of an involvement of fatty acid accumulation in the pathogenesis of preeclampsia (40). 
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1.2.3 Histologic Findings 
 
Higher rates of decidual arteriolopathy (both hypertrophic and atherosis), uterine 
pattern of chronic placental injury, villous infarctions and clusters of maternal floor 
multinucleate trophoblast are characteristic for preeclamptic lesions as well as HELLP 
syndrome (29, 41) (Figure 3). On a microscopic view the spiral and basal arteries are in a 
denser distribution pattern than usual, with smaller-caliber lumens and thicker walls (42), and 
increased numbers of immature villous trophoblast are also found (43). 
Maternal liver biopsy displays periportal and /or centrally localized parenchymal 
lesions with fibrin deposits (44). On hepatic imaging subcapsular hematoma and 
intraparenchymal hemorrhage might be seen (45). 
 
 
 
Figure 3. Microscopic image of acute atherosis in placenta from pregnancies complicated 
with preeclampsia, H&E staining, magnification x200  
(Figure taken from mentor’s archive) 
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1.3 Fas ligand 
 
The Fas/ Fas Ligand (also named Apo-1 or CD95) are members of the tumor necrosis 
factor family and play an important role in the regulation of cell death. The trimerization of 
the Fas receptor by Fas ligand results in the activation of caspase 8 and as a final consequence 
to an apoptotic cell death via the extrinsic pathway. Activation-induced cell death and the 
resulting T-cell homeostasis is a fundamental function of the Fas/Fas Ligand system. This 
limits T cell clone expansion and furthermore inactivates self-reactive T cells in the periphery.  
Lymphoproliferative disorders caused by defects in the genes encoding Fas and FasL 
clearly underline this modulatory function and its importance (46). While CD95 is abundantly 
expressed in various tissues, the expression of CD95L is limited to a few cell types, like 
activated T-cells, natural killer cells and cells of tissues of immune-privileged sites like testis 
and eye (47). In literature immune-privileged is defined as the capacity of a tissue to actively 
modulate the immune response in that specific location (48). The intervillous space as well as 
the placental bed sites present maternal fetal interfaces where trophoblastic cells and maternal 
lymphocytes meet. FasL expression in trophoblast plays also an important role in 
maintenance of immune-privilege of the placenta by inducing apoptosis of Fas-expressing 
lymphocytes of maternal origin. Several studies displayed FasL in microvesicles stored in 
cytoplasm of syncytiotrophoblast and secreted via exosomes. FasL expression was further 
detected in Hofbauer cells (49). One possible advantage of the exosome-associated secretion 
of FasL, opposite to the previous concept of membrane bound FasL, is the protection against 
an inflammatory response due to distance. It might additionally serve as a mechanism to 
induce apoptosis in fetus-sensitized Fas expressing effector cells further away from the 
placenta (49). FasL in trophoblast may also have the additional role of inducing apoptosis in 
the decidua and enable maternal invasion and implantation (50). 
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1.4 Fas ligand and its association with HELLP syndrome 
 
Since preeclampsia and HELLP syndrome seem both to be associated with a higher 
rates of trophoblast apoptosis than normal pregnancies and Fas/ FasL expression seems to be 
modified in preeclamptic patients, it seems that this alteration influences the pathogenesis of 
PE (11, 24, 35, 51, 52). The detection of specific polymorphisms encoding for Fas Ligand 
bearing a higher risk for the development of PE (18, 53) further enhances the theory of a 
possible causality between altered FasL expression and the development of PE. Moreover, the 
data by Strands suggested a pivotal role of placental derived FasL in liver damage of HELLP 
syndrome (36). In PE there seems to be an altered distribution of Th1/Th2 cells in comparison 
to normal pregnancy with a predominance of the more inflammation causing Th1 type (54).  
Latest findings also underlined the role of Treg/Th17 cells in immune tolerance in 
normal pregnancy (55) and displayed their lower numbers in preeclampsia (56). Interestingly 
Treg cells are highly sensitive to CD95-mediated apoptosis in comparison to other T cells 
(57).  
Literature search revealed a decreased FasL expression (51, 58, 59) and increased Fas 
expression in villous trophoblast of preeclamptic patients (51). While Petsas found FasL 
positive decidual macrophages only in preeclamptic patients (60), Eide claimed that FasL 
expressing decidual cells are also found in normal placentas and that they are reduced in 
preeclamptic patients. They further mention a higher reduction of FasL expressing decidual 
cells than EVTB in association with preeclamsia (59). This is contradictory to the finding of 
Mendilcioglu who found an increased expression of FasL in the decidua of patients with 
preeclampsia (61). In addition, a lower expression of CD95 on decidual Natural killer cells in 
the background of their ability to undergo Fas/FasL mediated apoptosis (62), could explain a 
higher inflammatory response in preeclamptic patients. Studies about an increase of soluble 
FasL concentrations in maternal blood seem inconsistent (59). Based on a review of previous 
studies we would suspect an increase in FasL expression in maternal decidual cells and 
hypothesize that this is the reason of an increase in apoptosis of trophoblast and prolonged 
survival of natural killer cells in the decidua, causing enhanced inflammation and 
corresponding symptoms in HELLP patients. 
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2. OBJECTIVES 
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The purpose of our study was to compare of the immunohistochemical staining for Fas 
Ligand on EVTB and DC in placentas with and without HELLP syndrome.  
According to our hypothesis the percentage of Fas Ligand expression should be higher 
in placentas with HELLP syndrome. We reason this increase with an enhanced apoptosis of 
trophoblast and prolonged survival of natural killer cells in the decidua.
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3. MATERIAL AND METHODS
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3.1. Material 
 
As sample ten placentae from women with HELLP syndrome were compared to the 
same number of normal placentae. HELLP syndrome was defined as follows: platelets 
<100x109/L, aspartate aminotransferase (AST) and alanine transaminase (ALT) >70U/L as 
well as lactic acid dehydrogenase (LDH) > 600U/L. All of the examined placentae were 
collected within 20 minutes after cesarean section and fixed in 10% formalin. The central part 
of the macroscopically normal placental disc, next to the umbilical cord was chosen for 
examination. The chorionic plate and the decidual floor were visible in each of the samples. 
To evaluate Fas Ligand expression we used immunohistochemistry and the semiquantitative 
HSCORE method. The assessment of the Fas Ligand distribution among the placentae was 
done manually using a x40 objective (Olympus BX41 microscope). 
  
 
 
15 
3.2 Immunohistochemical analysis 
 
All placenta-derived samples were prepared in the following way: the tissue was 
dewaxed in xylene, rehydrated in graded concentrations of alcohol and heated in a microwave 
oven for 20 minutes at 700W with TRIS/EDTA (pH 9; DAKO). After cooling to room 
temperature, samples were washed in distilled water and phosphate-buffered saline (PBS) 
solution (pH 7.5). By the usage of 3% H2O2 for 10 minutes’ endogenous peroxidase was 
blocked. Later on the samples were washed in distilled water to be prepared for 
immunohistochemical detection of FasL. Primary monoclonal mouse antibody (clone 5D1; 
Novocastra, Newcastle, UK), previously diluted 1: 50 was applied for one hour and then 
washed in PBS solution (pH 7.5). Additionally, EnVision HRP anti-mouse (K 4001; DAKO) 
was used was used as a secondary antibody; time of incubation was 30 minutes. After 
applying chromogen diaminobenzidine-hydrogen (DAB; code no. K 3468; DAKO) for 10 
minutes, the samples were washed in distilled water. The sections were counterstained in 
hematoxylin, dehydrated, cleared and mounted on silanized slides. The expression of FasL 
was characterized by a diffuse or granular brown staining of the cytoplasm (Figure 4 and 5). 
As control a sample of prostatic tissue and a sample of melanoma was used. We considered 
positive cells as cells with nuclei surrounded by positive cytoplasm. We graded the expression 
of FasL for EVTB by the HSCORE method using the equation HSCORE =Pi(i+1). In this 
equation the variable i should represent the intensity of staining with the following 
characteristics 1 (weak), 2 (moderate) or 3 (strong). Pi displays the percentage of stained 
trophoblast cells of each intensity (51). 
 
 3.3 Statistical analysis 
 
Our data was analyzed for statistical purposes with MedCalc software (MedCalc 
software, Mariakerke, Belgium). Data distribution was assessed by the Kolmogorov-Smirnov 
test. Afterwards statistical significance was assessed by the usage of the t-test for normally 
distributed values, while the Mann-Whitney test was used to study not normally distributed 
samples. Additionally, with the Chi-Square test we interpret the statistical significance of 
sampling distribution following a chi-squared curve. The data were displayed as means ±SD, 
or as medians with minimum and maximum range. Statistical significance was set at P < 0.05.
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4. RESULTS
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The samples in our study did not show any significant difference between studied 
groups in maternal age (t=1,417; P=0,173) and parity (Z=1,205; P=0,228). Gestational 
age was significantly lower in HELLP group compared with control group (Z=3,679; 
P=0,0002), as well as the birth weight (t=8,172; P<0,0001) IUGR was noted in 5 HELLP 
cases while here was none in control group which was statistically significant (χ2=6,333; 
DF=1; P=0,012) (Table 1). 
Table 1. Demographic and clinical characteristics of the study groups 
 HELLP 
(n=10) 
Control group 
 (n=10) 
 
P 
Maternal age (years) 29 ±8 33±4 0,173† 
Parity  1(1-6) 1(1-2) 0,228* 
Gestational age (weeks) 33 (28-37) 38 (37-39)  0,0002* 
Fetal weight (g) 1695±558 3550±450 <0,0001† 
IUGR 5 0 0,012** 
The results are presented as mean value ± SD for maternal age and fetal weight, and as 
median value (minimum and maximum value) for parity and gestational weeks. *Mann-
Whitney test; ** Chi-Square test, 
†
t-test 
 
 
EVTB FasL immunohistochemical expression was significantly higher in HELLP 
group compared to control group (Z=3,425; P=0,0006), as well as on DC (t=5,130; P=0,0001) 
(Figure 4&5). There was no statistically significant difference in FasL immunohistochemical 
expression between EVTB (3,9 (3-4)) and DC (3,85 (3-4)) in the HELLP group (Z=0,460; 
P=0,645). This correlates with the results of the control group where a significant difference 
between EVTB (2,5 (2-3,5)) and DC (2,8 (2-3,5)) FasL immunohistochemical expression 
could also not been shown (Z=0,229; P=0,818) (Table 2).  
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Figure 4. Immunohistochemical 
expression of Fas ligand on extravillous 
trophoblast and decidual cells in placenta 
from normal pregnancies, magnification 
x400 
(Image taken by candidate) 
 
Figure 5. Immunohistochemical 
expression of Fas ligand on extravillous 
trophoblast and decidual cells in placenta 
from pregnancy complicated with HELLP 
syndrome, magnification x400  
(Image taken by candidate) 
 
 
Table 2. Immunohistochemical expression of Fas ligand in extravillous trophoblast 
(EVTB) and decidual cells (DC) of placentas complicated by HELLP syndrome and 
control groups placentas.  
 HELLP 
(n=10) 
Control group 
(n=10) 
P 
EVTB 3,9 (3-4) 
 
2,5 (2-3,5) 0,0006* 
 
DC 
 
3,6 ±0,39 
 
 
2,7 ± 0,44 
 
0,0001
† 
The results are presented as mean value ± SD for DC, and as median value (minimum and 
maximum value) for EVTB. Results are presented as HSCORE. *Mann-Whitney test, 
†
t-test 
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5. DISCUSSION
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We were able to display a significantly higher FasL expression of the EVTB of 
placentae complicated by HELLP syndrome in our study. The insignificant difference in 
maternal age and parities between the two study groups confirmed an appropriately chosen 
sample. Meanwhile the significantly lower gestational age, birth weight and the IUGR in the 
HELLP group can be attributed as part of the clinical expression of HELLP syndrome and its 
consequence of preterm delivery. GA- matching between groups was not possible which 
might lead to an altered estimation of the observed difference in FasL expression (59). The 
expression of FasL on trophoblast supports the theory of their role as immune privileged cells 
maintaining the fetal allograft via the Fas/ FasL pathway (50). Higher levels of FasL in 
maternal blood serum seem to be connected to an enhanced inflammatory immune response in 
HELLP syndrome (19). Moreover, the hepatic injury, which is a characteristic part of HELLP 
syndrome, seems also to be caused by placenta-derived FasL (CD95L) which is toxic to 
human hepatocytes (36). Therefore, we interpret the increase in FasL expression on EVTB in 
placenta with HELLP syndrome as a possible cause for an increased immune response and the 
following damage. The increased expression of FasL in EVTB is coherent with previous 
findings of increased FasL in villous trophoblast (24). 
To the best of our knowledge, this study is the ﬁrst one to reveal information regarding 
the expression of FasL on EVTB of HELLP syndrome placentae.  
The higher expression of FasL on EVTB and decidual cells in patients with HELLP 
seems to be in contrast to the findings of reduced FasL /Fas expression in both decidual cells 
and EVTB in patients with preeclampsia found by Eide, Darmochwal-Kolarz (59, 62). This 
might indicate that preeclampsia and HELLP syndrome differ in their pathophysiological 
mechanisms and should be treated as different entities and not as variations of the same 
syndrome. Higher expression of FasL together with a rise in trophoblast turnover could be a 
cause for more severe symptoms and disastrous outcomes in HELLP syndrome than in PE. 
In regard to clinical practice this study and its finding of higher FasL expression in 
EVTB may offer a way of early detection of the syndrome by determination of higher FasL 
expression in the placentae and sera of the mother. Another study was able to display 
significantly higher ATI-AAs in the HELLP group of pregnant rats and correlate with them 
with an increased level of TNF-alpha and ET-1 in plasma (41).  
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ATI-AAs are agonistic autoantibodies (Aas) binding to the angiotensin II type 1 (AT) 
receptor, offering another approach to the pathophysiological mechanism of HELLP 
syndrome and another possibility for early detection of immunologic markers in blood 
samples of patients with HELLP syndrome which offer a way of prompt detection in clinical 
practice (41). 
The major limitation of the present study is the number of the placental samples, as well as 
the gestational age mismatch between the HELLP and control group. Additionally, further 
methods than immunohistochemistry, like Western blot or PCR could have been used to 
verify the results.  
Nevertheless, we were able to find a significantly higher immunohistochemical 
expression of FasL on EVTB and DC in HELLP group patients compared to the control group 
in our study, while there was no statistically significant difference in FasL expression between 
EVTB and decidual cells for each studied placental group. In addition, we recognized 
different immunohistochemical staining patterns for FasL expression between our HELLP 
syndrome samples and the in literature described staining pattern of preeclampsia with a 
higher staining for FasL in HELLP syndrome. The results of our study offer a possibility of 
further research in new diagnostic tool for early detection of HELLP syndrome. 
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6. CONCLUSIONS
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1. In our study we were able to display a significantly higher immunohistochemical 
expression of FasL on EVTB and DC in HELLP group patients compared to the 
control group. However, we were not able to reveal a statistically significant 
difference in FasL immunohistochemical expression between EVTB and decidual 
cells for each studied placental group. 
2. The results of our study are in coherence with previous studies of FasL expression in 
placentae complicated by HELLP syndrome. 
3. The immunohistochemical staining of FasL differs between HELLP syndrome and 
preeclampsia. 
4. Increased FasL expression in decidual cells and EVTB are an indicator for the 
pathology of HELLP syndrome and in further research may offer a way of early 
detection of the syndrome due to soluble FasL in maternal serum as clinical marker.  
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8. SUMMARY
  
 
 
32 
Objectives: to compare the staining for Fas Ligand receptor on EVTB in placentas with and 
without HELLP syndrome. Maternal and gestational age, as well as parity, fetal weight and 
IUGR were also investigated and analyzed for differences.  
Subject and method: 10 placentae with HELLP syndrome and 10 control placentae were 
enrolled in the study. Both groups were immunohistochemically stained with antibody to 
FasL. We used the HSCORE method for assessment of the immunohistochemical staining of 
FasL in each sample group.  
Results: We were able to show a statistically significant increase in FasL expression on 
EVTB and DC in the placentae of patients with HELLP syndrome compared to the control 
group. No statistically difference in the immunohistochemical expression between EVTB and 
DC could be found in the HELLP or control group.  
Conclusion: Our study has shown a higher occurrence of FasL in placentae of pregnancies 
complicated by HELLP syndrome. Possibly this is causing higher rates of apoptosis and 
following inflammatory response at the decidual side and thereby leading to the clinical 
picture of HELLP syndrome. Further investigations with larger sample are required to 
confirm the results of the presented study.  
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9. CROATIAN SUMMARY
  
 
 
34 
Ciljevi: usporediti imunohistokemijski izražaj Fas liganda (FasL) na ekstraviloznom 
trofoblastu (EVTB) i decidualnim stanicama (DC) u posteljicama kompliciranim HELLP 
sindromom te rezultate usporediti s posteljicama normalnih trudnoća. Dob majke, gestacijska 
dob, paritet, porođajna masa te intruterini zastoj rasta (IUZR) su također analizirani i 
uspoređeni između istraživanih skupina.  
Ispitanici i metode: 10 posteljica iz trudnoća kompliciranim HELLP sindromom i jednak 
broj posteljica urednih trudnoća je uključen u studiju. Semikvantitativna HSCORE metoda je 
korištena za procjenu FasL imunohistokemijskog izražaja, zasebno za EVTB i DC. 
Rezultati: imunohistokemijki izražaj FasL je bio statistički značajno veći u EVTB I DC u 
posteljicama trudnoća kompliciranim HELLP sindromom u usporedbi s kontrolnom 
skupinom posteljica. Nije bilo statsistčki značajne razlike u FasL izražaju između EVTB i DC 
u svakoj ispitivanoj grupi posteljica.  
Zaključak: veći imunohistokemijski izražaj FasL na EVTB i DC u posteljicama 
kompliciranim HELLP sindromom mogao bi doprinjeti razvoju kliničkih karakteristika 
HELLP sindroma. Potrebne su daljnje studije s većim uzorkom posteljica kako bi se rezultati 
ovog istraživanja potvrdili.  
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